Back to Search Start Over

Negative-Pressure Wound Therapy Versus Standard Treatment of Adult Patients With Conflict-Related Extremity Wounds: Protocol for a Randomized Controlled Trial.

Authors :
Älgå A
Wong S
Haweizy R
Conneryd Lundgren K
von Schreeb J
Malmstedt J
Source :
JMIR research protocols [JMIR Res Protoc] 2018 Nov 26; Vol. 7 (11), pp. e12334. Date of Electronic Publication: 2018 Nov 26.
Publication Year :
2018

Abstract

Background: In armed conflict, injuries commonly affect the extremities and contamination with foreign material often increases the risk of infection. The use of negative-pressure wound therapy has been described in the treatment of acute conflict-related wounds, but reports are retrospective and with limited follow-up.<br />Objective: The objective of this study is to investigate the effectiveness and safety of negative-pressure wound therapy use in the treatment of patients with conflict-related extremity wounds.<br />Methods: This is a multisite, superiority, pragmatic randomized controlled trial. We are considering for inclusion patients 18 years of age and older who are presenting with a conflict-related extremity wound within 72 hours after injury. Patients are block randomly assigned to either negative-pressure wound therapy or standard treatment in a 1:1 ratio. The primary end point is wound closure by day 5. Secondary end points include length of stay, wound infection, sepsis, wound complications, death, and health-related quality of life. We will explore economic outcomes, including direct health care costs and cost effectiveness, in a substudy. Data are collected at baseline and at each dressing change, and participants are followed for up to 3 months. We will base the primary statistical analysis on intention-to-treat.<br />Results: The trial is ongoing. Patient enrollment started in June 2015. We expect to publish findings from the trial by the end of 2019.<br />Conclusions: To the best of our knowledge, there has been no randomized trial of negative-pressure wound therapy in this context. We expect that our findings will increase the knowledge to establish best-treatment strategies.<br />Trial Registration: ClinicalTrials.gov NCT02444598; http://clinicaltrials.gov/ct2/show/NCT02444598 (Archived by WebCite at http://www.webcitation.org/72hjI2XNX).<br />International Registered Report Identifier (irrid): DERR1-10.2196/12334.<br /> (©Andreas Älgå, Sidney Wong, Rawand Haweizy, Kalle Conneryd Lundgren, Johan von Schreeb, Jonas Malmstedt. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 26.11.2018.)

Details

Language :
English
ISSN :
1929-0748
Volume :
7
Issue :
11
Database :
MEDLINE
Journal :
JMIR research protocols
Publication Type :
Academic Journal
Accession number :
30478024
Full Text :
https://doi.org/10.2196/12334